Patents by Inventor Claire M. Fraser
Claire M. Fraser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8715688Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: providing an antibody preparation, providing at least one expression library, identifying antigens which bind, screening the identified antigens, identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.Type: GrantFiled: September 13, 2012Date of Patent: May 6, 2014Assignee: Valneva Austria GmbHInventors: Andreas Meinke, Eszter Nagy, Uwe Von Ahsen, Christoph Klade, Tamas Henics, Wolfgang Zauner, Duc Bui Minh, Oresta Vytvytska, Hildegard Etz, Agnieszka Dryla, Thomas Weichhart, Martin Hafner, Brigitte Tempelmaier, Claire M. Fraser, Steven Gill
-
Publication number: 20130034575Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: providing an antibody preparation, providing at least one expression library, identifying antigens which bind, screening the identified antigens, identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.Type: ApplicationFiled: September 13, 2012Publication date: February 7, 2013Applicant: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Uwe Von Ahsen, Christoph Klade, Tamas Henics, Wolfgang Zauner, Duc Bui Minh, Oresta Vytvytska, Hildegard Etz, Agnieszka Dryla, Thomas Weichhart, Martin Hafner, Brigitte Tempelmaier, Claire M. Fraser, Steven Gill
-
Patent number: 8323660Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps:—providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—screening said at least one expression library with said antibody preparation,—identifying antigens which bind in said screening to antibodies in said antibody preparation,—screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogenType: GrantFiled: August 9, 2010Date of Patent: December 4, 2012Assignee: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Uwe Von Ahsen, Christoph Klade, Tamas Henics, Wolfgang Zauner, Duc Bui Minh, Oresta Vytvytska, Hildegard Etz, Agnieszka Dryla, Thomas Weichhart, Martin Hafner, Brigitre Tempelmaier, Claire M. Fraser, Steven Gill
-
Patent number: 7988979Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.Type: GrantFiled: January 11, 2008Date of Patent: August 2, 2011Assignees: J. Craig Venter Institute, Inc., Novartis AGInventors: Claire M. Fraser, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Maria Rosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulo Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, Craig Venter
-
Patent number: 7968297Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: —providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —screening said at least one expression library with said antibody preparation, —identifying antigens which bind in said screening to antibodies in said antibody preparation, —screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific patType: GrantFiled: January 21, 2002Date of Patent: June 28, 2011Assignee: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Uwe Von Ahsen, Christoph Klade, Tamas Henics, Wolfgang Zauner, Duc Bui Minh, Oresta Vytvytska, Hildegard Etz, Agnieszka Dryla, Thomas Weichhart, Martin Hafner, Brigitte Tempelmaier, Claire M. Fraser, Steven Gill
-
Publication number: 20110020402Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps:—providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogren, tumor, allergen or tissue or host prone to auto-immunity,—providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—screening said at least one expression library with said antibody preparation, identifying antigens which bind in said screening to antibodies in said antibody preparation, —screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogType: ApplicationFiled: August 9, 2010Publication date: January 27, 2011Inventors: Andreas Meinke, Eszter Nagy, Uwe Von Ahsen, Christoph Klade, Tamas Henics, Wolfgang Zauner, Duc Bui Minh, Oresta Vytvytska, Hildegard Etz, Agnieszka Dryla, Thomas Weichhart, Martin Hafner, Brigitre Tempelmaier, Claire M. Fraser, Steven Gill
-
Publication number: 20100233677Abstract: Infection by human rhinovirus (HRV) causes upper and lower respiratory tract disease with varying degrees of virulence. The molecular basis of diversity was examined by completing the genome sequences for all known serotypes (n=99) as well as novel field samples. Superimposition of capsid crystal structure and optimal-energy RNA configurations established the alignments. The phylogeny revealed conserved motifs, Glade-specific diversity including a potential new species (clade-D), pan-genome mutations in field isolates, and unexpected recombination that contributes to heterogeneity. A spacer tract near a 5?-UTR cloverleaf was hypervariable, and in analogy with poliovirus, may be associated with virulence. A previously unidentified configuration consistent with non-scanning internal ribosome entry may account for rapid protein translation.Type: ApplicationFiled: February 9, 2010Publication date: September 16, 2010Inventors: Stephen B. Liggett, Claire M. Fraser-Liggett, Ann C. Palmenberg
-
Patent number: 7771728Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: —providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —screening said at least one expression library with said antibody preparation, —identifying antigens which bind in said screening to antibodies in said antibody preparation, —screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific patType: GrantFiled: December 21, 2006Date of Patent: August 10, 2010Assignee: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Uwe Von Ahsen, Christoph Klade, Tamas Henics, Wolfgang Zauner, Duc Bui Minh, Oresta Vytvytska, Hildegard Etz, Agnieszka Dryla, Thomas Weichhart, Martin Hafner, Brigitte Tempelmaier, Claire M. Fraser, Steven Gill
-
Publication number: 20100015151Abstract: Various specific meningococcal proteins are disclosed. The invention provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by meningococcus, such as bacterial meningitis.Type: ApplicationFiled: June 29, 2007Publication date: January 21, 2010Inventors: Rino Rappuoli, Claire M. Fraser, Mariagrazia Pizza, Maria Scarselle, David Serruto, Herve Tettelin
-
Publication number: 20080317754Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Type: ApplicationFiled: June 1, 2007Publication date: December 25, 2008Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
-
Patent number: 7235371Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Type: GrantFiled: July 21, 2005Date of Patent: June 26, 2007Assignees: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
-
Patent number: 7087410Abstract: The present invention relates to an expression system for the expression of proteins and peptides in a methanotrophic bacterium, preferable the M. capsulatus. Further, the invention relates to the exportation and display of said peptides and proteins on the surface of said bacteria. The invention also describes a method for the production of a desired protein in the M. capsulatus.Type: GrantFiled: January 14, 2002Date of Patent: August 8, 2006Inventors: Nils Kåre Birkeland, Ingvar Eidhammer, Inge Jonassen, Harald B. Jensen, Torleiv Lien, Johan R. Lillehaug, Ivar Lossius, Jonathan A. Eisen, Claire M. Fraser, A. Scott Durkin, Steven L. Salzberg
-
Patent number: 6994978Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Type: GrantFiled: December 4, 2003Date of Patent: February 7, 2006Assignees: Human Genome Sciences, Inc., SmithKline Beecham CorporationInventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
-
Publication number: 20040175705Abstract: The present invention related to an expression system for the expression of proteins and peptides in a methanotrophic bacterium preferable the M. capsulatus. Further, the invention relates to the exportation and display of said peptides and proteins on the surface of said bacteria. The Invention also describes a method for the production of a desired protein in the M. capsulatus.Type: ApplicationFiled: July 11, 2003Publication date: September 9, 2004Inventors: Nils Kare Birkeland, Ingvar Eidhammer, Inge Jonassen, Harald B Jensen, Torleiv Lien, Johan R Lillehaug, Ivar Lossius, Jonathan A Eisen, Claire M Fraser, A Scott Durkin, Steven L Salzberg
-
Patent number: 6680375Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Type: GrantFiled: April 3, 2002Date of Patent: January 20, 2004Assignees: Human Genome Sciences, Inc., SmithKline Beecham CorporationInventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
-
Patent number: 6635252Abstract: Polynucleotides which encode the polypeptide SOD-4, as well as such polypeptides, and antibodies against the polypeptide and the use of the polypeptide as a pharmaceutical for treating cerebral ischaemia, ulcers, inflammation, arrhythmia, oedema and paraquat intoxication as well as rheumatoid arthritis, osteoarthritis and radiation injury.Type: GrantFiled: June 20, 2001Date of Patent: October 21, 2003Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Craig A. Rosen, Claire M. Fraser, Jeannine D. Gocayne
-
Patent number: 6620619Abstract: The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins. The DNA repair proteins may be produced by recombinant DNA techniques. One of the human DNA repair proteins, hmlh1, has been mapped on chromosome 3. The polynucleotide sequences of DNA repair proteins may be used for diagnosis of a hereditary susceptibility to cancer.Type: GrantFiled: March 16, 1994Date of Patent: September 16, 2003Assignee: Human Genome Sciences, Inc.Inventors: William A. Haseltine, Steven Ruben, Ying-Fei Wei, Mark D. Adams, Robert D. Fleischmann, Claire M. Fraser, Craig A. Rosen, Rebecca A. Fuldner, Ewen F. Kirkness
-
Publication number: 20030170663Abstract: The present invention provides the nucleotide sequence of the entire genome of Mycoplasma genitalium, SEQ ID NO: 1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies protein encoding fragments of the genome, and identifies, by position relative to two (2) genes known to flank the origin of replication, any regulatory elements which modulate the expression of the protein encoding fragments of the Mycoplasma genitalium genome.Type: ApplicationFiled: July 26, 2002Publication date: September 11, 2003Applicant: Johns Hopkins UniversityInventors: Claire M. Fraser, Mark D. Adams, Jeannine D. Gocayne, Clyde A. Hutchison, Hamilton O. Smith, J. Craig Venter, Owen R. White
-
Patent number: 6610477Abstract: The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins and a procedure for producing such proteins by recombinant techniques. One of the human DNA repair proteins, hMLH1, has been mapped to chromosome 3 while hMLH2 has been mapped to chromosome 2 and hMLH3 has been mapped to chromosome 7. The polynucleotide sequences of the DNA repair proteins may be used for therapeutic and diagnostic treatments of a hereditary susceptibility to cancer.Type: GrantFiled: June 6, 1995Date of Patent: August 26, 2003Assignees: Human Genome Sciences, Inc., The Johns Hopkins UniversityInventors: William A. Haseltine, Steven M. Ruben, Ying-Fei Wei, Mark D. Adams, Robert D. Fleischmann, Claire M. Fraser, Rebecca A. Fuldner, Ewen F. Kirkness, Craig A. Rosen, Bert Vogelstein, Kenneth W. Kinzler, Nicholas C. Nicolaides, Nickolas Papadopoulos
-
Publication number: 20030087226Abstract: The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins. The DNA repair proteins may be produced by recombinant DNA techniques. One of the human DNA repair proteins, hmlh1, has been mapped on chromosome 3. The polynucleotide sequences of DNA repair proteins may be used for diagnosis of a hereditary susceptibility to cancer.Type: ApplicationFiled: March 16, 1994Publication date: May 8, 2003Inventors: WILLIAM A. HASELTINE, STEVEN RUBEN, YING-FEI WEI, MARK D. ADAMS, ROBERT D. FLEISCHMANN, CLAIRE M. FRASER, CRAIG A. ROSEN, REBECCA A. FULDNER, EWEN F. KIRKNESS